Home Use of an Artificial Beta Cell in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The feasibility, safety, and efficacy of prolonged use of an artificial beta cell (closed-loop insulin-delivery system) in the home setting have not been established. METHODS: In two multicenter, crossover, randomized, controlled studies conducted under free-living home conditions, we compared closed-loop insulin delivery with sensor-augmented pump therapy in 58 patients with type 1 diabetes. The closed-loop system was used day and night by 33 adults and overnight by 25 children and adolescents. Participants used the closed-loop system for a 12-week period and sensor-augmented pump therapy (control) for a similar period. The primary end point was the proportion of time that the glucose level was between 70 mg and 180 mg per deciliter for adults and between 70 mg and 145 mg per deciliter for children and adolescents. RESULTS: Among adults, the proportion of time that the glucose level was in the target range was 11.0 percentage points (95% confidence interval [CI], 8.1 to 13.8) greater with the use of the closed-loop system day and night than with control therapy (P<0.001). The mean glucose level was lower during the closed-loop phase than during the control phase (difference, -11 mg per deciliter; 95% CI, -17 to -6; P<0.001), as were the area under the curve for the period when the glucose level was less than 63 mg per deciliter (39% lower; 95% CI, 24 to 51; P<0.001) and the mean glycated hemoglobin level (difference, -0.3%; 95% CI, -0.5 to -0.1; P=0.002). Among children and adolescents, the proportion of time with the nighttime glucose level in the target range was higher during the closed-loop phase than during the control phase (by 24.7 percentage points; 95% CI, 20.6 to 28.7; P<0.001), and the mean nighttime glucose level was lower (difference, -29 mg per deciliter; 95% CI, -39 to -20; P<0.001). The area under the curve for the period in which the day-and-night glucose levels were less than 63 mg per deciliter was lower by 42% (95% CI, 4 to 65; P=0.03). Three severe hypoglycemic episodes occurred during the closed-loop phase when the closed-loop system was not in use. CONCLUSIONS: Among patients with type 1 diabetes, 12-week use of a closed-loop system, as compared with sensor-augmented pump therapy, improved glucose control, reduced hypoglycemia, and, in adults, resulted in a lower glycated hemoglobin level. (Funded by the JDRF and others; AP@home04 and APCam08 ClinicalTrials.gov numbers, NCT01961622 and NCT01778348.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Medtronic 780G, 113,114 CamAPS FX, 115,116 and Diabeloop 117 received CE mark for use in European countries;”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [115]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
The barrier of hypoglycemia in diabetes
Cryer, P. E. (2008) · Diabetes · doi:10.2337/db08-1084 · Cited by 725
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 3×
“Hyperglycemia related to infusion-set occlusion 0 6 (18) 4 (12) 0 0 2 (8) 0 0”
Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes
Russell, S. J., El-Khatib, F. H., Sinha, M., Magyar, K. L., McKeon, K., Goergen, L. G., Balliro, C., Hillard, M. A., Nathan, D. M., & Damiano, E. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314474 · Cited by 602 · cited 2×
“Hyperglycemia related to infusion-set occlusion 0 6 (18) 4 (12) 0 0 2 (8) 0 0”
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541
Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes Camp
Phillip, M., Battelino, T., Atlas, E., Kordonouri, O., Bratina, N., Miller, S., Biester, T., Avbelj Stefanija, M., Muller, I., Nimri, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1206881 · Cited by 435
Wood, J. R., Miller, K. M., Maahs, D. M., Beck, R. W., DiMeglio, L. A., Libman, I. M., Quinn, M., Tamborlane, W. V., Woerner, S. E., & for the T1D Exchange Clinic Network (2013) · Diabetes Care · doi:10.2337/dc12-1959 · Cited by 415
Ly, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411
McKnight, J. A., Wild, S. H., Lamb, M. J. E., Cooper, M. N., Jones, T. W., Davis, E. A., Hofer, S., Fritsch, M., Schober, E., Svensson, J., et al. (2015) · Diabetic Medicine · doi:10.1111/dme.12676 · Cited by 343 · cited 6×
“Knee-joint arthralgia 0 1 (3) 0 0 0 0 0 0”
InfluentialClosed-loop insulin delivery from bench to clinical practice
Hovorka, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.32 · Cited by 342 · cited 1×
“Gastroenteritis 0 2 (6) 3 (9) 0 0 0 0 0”
Self-citation
Cited by
Items 401–454 of 454
Key Developments in Pediatric Endocrinology in 2015
Eshragh, N., & LAFRANCHI, S. H. (2016) · US Endocrinology · doi:10.17925/use.2016.12.02.87
Diabète de type1: pompeàinsuline
Renard, É. (2017) · doi:10.1016/b978-2-294-74646-8.00008-0
Meta-analysis of artificial pancreas trials: methodological considerations – Authors' reply
Weisman, A., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30237-1
Jallon, P., Lachal, S., Franco, C., Charpentier, G., Huneker, E., Doron, M., Franc, S., Benhamou, P.-Y., Borot, S., Guerci, B., et al. (2017) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2017.8037108 · Cited by 1
Real-World Challenges of Controller Adaptation with the Artificial Pancreas
Bally, L., & Thabit, H. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0310
“This perhaps was unsurprising, as others have similarly shown that the benefit of day-andnight closed loop use was more apparent during the overnight period.(5,15,16) Despite adaptive controllers, the barriers to daytime closed-loop performance are the relative delay of subcutaneous insulin action profile(17) and sens…”
Self-citationAuf dem Weg zum Closed-Loop – Ziel und Realität
Biester, T., Danne, T., & Kordonouri, O. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-123111
Auf dem Weg zum Closed-Loop – Ziel und Realität
Biester, T., Danne, T., & Kordonouri, O. (2018) · Diabetes aktuell · doi:10.1055/a-0622-7858
Avancées technologiques et traitement du diabète
Roy‐Fleming, A., & Taleb, N. (2018) · Nutrition, science en évolution · doi:10.7202/1048943ar · Cited by 1
“Jusqu’à ce jour, les études du PA les plus longues ( jusqu’à 3 mois) ayant été publiées ne concernaient que le PA mono-hormonal ; elles ont permis de détecter une diminution de l’HbA1c de 0,3 à 0,5 % [34, 35].”
11th Annual Symposium on Self-Monitoring of Blood Glucose: April 12–14, 2018, Oslo, Norway
Parkin, C. G., Homberg, A., & Hinzmann, R. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0284
Glycaemic control in pregnancies complicated by type 1 diabetes
Stewart, Z. A. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.23269 · Cited by 1
So viel Technik kann auch überfordern
Klein, F. (2018) · Info Diabetologie · doi:10.1007/s15034-018-1414-1
Quel scénario pour le déploiement de l'insulinothérapie automatisée en boucle fermée ?
Benhamou, P., Franc, S., Hanaire, H. P., Penfornis, A., & Charpentier, G. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30176-7
Renard, É. (2019) · Springer eBooks · doi:10.1007/978-3-319-98119-2_6
Bringer, J., Place, J., & Renard, É. (2017) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30415-7 · Cited by 1
A Hybrid Closed-loop Insulin Delivery System for the Treatment of Type I Diabetes
Moses, E. F. (2019) · Pondicherry Journal of Nursing · doi:10.5005/jp-journals-10084-12104
The dawn of automated insulin delivery: from promise to product
Nally, L. M., & Sherr, J. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816714-4.00016-8
Burn, M. S., Burn, S. C., & Burn, P. (2019) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2019.06.00182
Using the Novel Approach of an Artificial Pancreas to Manage Type 1 Diabetes Mellitus in Pregnancy
Lefkovits, Y. R., Stewart, Z., & Murphy, H. R. (2019) · European Medical Journal · doi:10.33590/emj/10312967
„Nichtärztliche“ Insulindosisanpassung
Wiesner, T. (2021) · Diabetes aktuell · doi:10.1055/a-1555-2606
“[18] Thabit H, Tauschmann M, Allen JM et al.”
Background“Closed Loop” Insulin Delivery
Hovorka, R., & Boughton, C. K. (2022) · doi:10.1093/med/9780198870197.003.0264
Self-citationGlandt, M., & Bloomgarden, Z. T. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_48-1
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Glandt, M., & Bloomgarden, Z. T. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_48
Therapy of Type 1 Diabetes Mellitus
Omura, E., & Peters, A. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_43-1
Therapy of Type 1 Diabetes Mellitus
Omura, E., Cohan, P., & Peters, A. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_43
Estrategias de control avanzadas para páncreas artificial
Fushimi, E. (2021) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/133534
(2020) · Wiener klinische Wochenschrift · doi:10.1007/s00508-020-01674-1
Kowalski, A. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815655-1.00008-9
Closed-Loop Visceral Bioelectronics Therapies
Raczkowska, M. N., & Thakor, N. V. (2022) · Handbook of Neuroengineering · doi:10.1007/978-981-15-2848-4_118-1
Fear of hypoglycemia: a new therapeutic target
Chernaya, M. E., Nersesyan, A. A., Ostroukhova, E. N., & Volkova, A. R. (2022) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2022-11-4-70-77
RESISTENCIAS O MAL USO DE LOS ANTIBIÓTICOS
SERRANO, T. B. (2022) · doi:10.59466/lc12022cs2024
Jiao, X., & Shen, Y. (2023) · Journal of Diabetes and Clinical Research · doi:10.33696/diabetes.4.055
“The analysis included ten articles [1-10], covering 11 studies with 817 participants.”
BackgroundHatulely, C. A. (2023) · Journal of Advance Research in Medical & Health Science · doi:10.53555/nnmhs.v9i8.1807
Continuous subcutaneous insulin infusion: a local perspective
Yau, T., Jenkins, A. J., & Ronald, C. W. (2023) · Hong Kong Medical Journal · doi:10.12809/hkmj219644
Erste pädiatrische Nutzung eines AID-Systems mit automatischem Korrekturbolus in Deutschland
Berge, T. V. D., Biester, S., Remus, K., Reschke, F., Klusmeier, B., Adolph, K., Kordonouri, O., Danne, T., & Biester, T. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2131-5432
“Eine Weiterentwicklung besteht in hybriden Systemen mit geschlossenem Regelkreis, bei denen der Algorithmus die Basalinsulinabgabe [6] und bei einigen Systemen auch Korrekturbolusgaben auf der Grundlage von CGM-Daten steuert, während die Anwendenden weiterhin manuell Bolusgaben zu den Mahlzeiten vornehmen [7].”
BackgroundEinblick in die Glukosewerte unter Real-World-Bedingungen
Thomas, A. (2023) · Info Diabetologie · doi:10.1007/s15034-023-4587-1
Iqbal, A., Chow, E., Jones, T. W., & Heller, S. R. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch40
(2024) · American Diabetes Association eBooks · doi:10.2337/9781580408363.ch04
TRATAMIENTO FARMACOLÓGICO Y FACTORES DE RIESGO EN FRACTURAS POR FRAGILIDAD
LÓPEZ, M. D. R. (2022) · doi:10.59466/lc2024cs010
Diabete di tipo 1: l’evoluzione della tecnologia al servizio del paziente
Tinti, D., & Nobili, C. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01650-9
Pawar, A. D., Rohile, S. B., & D., S. S. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-29628
Kang, S. L., Hwang, Y. N., Kwon, J. Y., & Kim, S. M. (2024) · Figshare · doi:10.6084/m9.figshare.26552224
Godoi, A., Reis Marques, I., Padrão, E. M. H., Mahesh, A., Hespanhol, L. C., Riceto Loyola Júnior, J. E., de Souza, I. A. F., Moreira, V. C. S., Silva, C. H., Miyawaki, I. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26620396
Guía de práctica clínica sobre Diabetes Mellitus Tipo 1
(2026) · GuíaSalud eBooks · doi:10.46995/gpc_659
L’insulinothérapie automatisée : du concept à la pratique clinique, une évolution ininterrompue
Renard, É. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.02.013
Bratychak, M., Земке, В. М., & Bolinovskyi, Y. A. (2026) · Chemistry Technology and Application of Substances · doi:10.23939/ctas2026.01.179
Advanced Technology in Diabetes: Sensors and Pumps
Forlenza, G. P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00023-8
Burnside, M. (2023) · Otago University Research Archive (University of Otago)
Initiation of Continuous Glucose Monitoring and Insulin Pump Therapy
Hindmarsh, P. C., Gupta, A., Swart, A., & Cooper, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-24854-1_6
Self-citationHohendorff, J., Klupa, T., Wrobel, M., Grzelka‐Wozniak, A., Sochacka-Tatara, E., PLONKA-STEPIEN, M., Zych, Z., Matejko, B., ADAMCZYK-HOHENDORFF, M. M., Rokicka, D., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71339
Światlak, K., Trzaskalik, J., Żelazna, W., Sokołowski, J., & Leśniak, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(52).2026.6584
Metadata
- Authors
- Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., Mader, J. K., Holzer, M., Kojzar, H., Exall, J., Yong, J., Pichierri, J., Barnard, K. D., Kollman, C., Cheng, P., Hindmarsh, P. C., Campbell, F. M., Arnolds, S., Pieber, T. R., Evans, M. L., Dunger, D. B., & Hovorka, R.
- Affiliations
- University of Cambridge (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Profil Institute for Metabolic Research (DE)
- Medical University of Graz (AT)
- Leeds Teaching Hospitals NHS Trust (GB)
- University College Hospital (GB)
- Bournemouth University (GB)
- Jaeb Center for Health Research (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2129-2140
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4697362
- OpenAlex
- W2332531077
- Cited by
- 450
- References
- 29
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 23 · 2023: 29 · 2022: 31 · 2021: 43 · 2020: 34 · 2019: 49 · 2018: 71 · 2017: 71 · 2016: 68 · 2015: 10
- FWCI
- 63.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Funders
- Wellcome Trust (100574, 100574/Z/12/Z)
- National Institute for Health and Care Research (NF-SI-0508-10274, NF-SI-0513-10012, CAMBRC-2012-1)
- Swansea University
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, artificial pancreas, artificial beta cell, sensor-augmented pump therapy, glycemic variability, HbA1c, children and adolescents, adults, continuous glucose monitoring, insulin pump therapy, free-living conditions, hypoglycemia risk reduction, glycemic control
- MeSH terms
- Adolescent, Adult, Algorithms, Child, Diabetes Mellitus, Type 1, Equipment Design, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Infusion Pumps, Implantable, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.